HK1084602A1 - Tricyclic parp inhibitors - Google Patents
Tricyclic parp inhibitorsInfo
- Publication number
- HK1084602A1 HK1084602A1 HK06106961.6A HK06106961A HK1084602A1 HK 1084602 A1 HK1084602 A1 HK 1084602A1 HK 06106961 A HK06106961 A HK 06106961A HK 1084602 A1 HK1084602 A1 HK 1084602A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- parp inhibitors
- tricyclic
- lactam
- relates
- tricyclic parp
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/02—Pentosyltransferases (2.4.2)
- C12Y204/0203—NAD+ ADP-ribosyltransferase (2.4.2.30), i.e. tankyrase or poly(ADP-ribose) polymerase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0317466.1A GB0317466D0 (en) | 2003-07-25 | 2003-07-25 | Use |
GB0408524A GB0408524D0 (en) | 2004-04-16 | 2004-04-16 | Use |
PCT/GB2004/003183 WO2005012305A2 (en) | 2003-07-25 | 2004-07-23 | Tricyclic parp inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1084602A1 true HK1084602A1 (en) | 2006-08-04 |
Family
ID=34117642
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK06106961.6A HK1084602A1 (en) | 2003-07-25 | 2006-06-19 | Tricyclic parp inhibitors |
Country Status (23)
Country | Link |
---|---|
US (2) | US7351701B2 (xx) |
EP (1) | EP1660095B1 (xx) |
JP (2) | JP5466814B2 (xx) |
KR (1) | KR101138471B1 (xx) |
AT (1) | ATE454893T1 (xx) |
AU (1) | AU2004261462B2 (xx) |
BR (1) | BRPI0412899B1 (xx) |
CA (1) | CA2533332C (xx) |
CY (1) | CY1110335T1 (xx) |
DE (1) | DE602004025123D1 (xx) |
DK (1) | DK1660095T3 (xx) |
ES (1) | ES2339663T3 (xx) |
HK (1) | HK1084602A1 (xx) |
IL (1) | IL173336A (xx) |
MX (1) | MXPA06000993A (xx) |
NO (1) | NO334610B1 (xx) |
NZ (1) | NZ544989A (xx) |
PL (1) | PL1660095T3 (xx) |
PT (1) | PT1660095E (xx) |
RU (1) | RU2404183C2 (xx) |
SI (1) | SI1660095T1 (xx) |
WO (1) | WO2005012305A2 (xx) |
ZA (1) | ZA200600679B (xx) |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20030020488A (ko) * | 2001-08-29 | 2003-03-10 | 강정훈 | 대나무 추출물을 유효성분으로 하는 화상치료용 조성물 |
BRPI0408996A (pt) * | 2003-03-31 | 2006-03-28 | Pfizer | saia de inibidores tricìclicos de poli(adpp-ribose) polimerases |
GB0317466D0 (en) * | 2003-07-25 | 2003-08-27 | Univ Sheffield | Use |
MXPA06000993A (es) | 2003-07-25 | 2006-08-31 | Cancer Rec Tech Ltd | Inhbidores triciclicos de parp. |
DK2305221T3 (en) * | 2003-12-01 | 2015-08-24 | Kudos Pharm Ltd | DNA damage repair inhibitors for the treatment of cancer |
BRPI0516766A (pt) * | 2004-09-22 | 2008-09-16 | Pfizer | formas polimórficas e amorfas do sal de fosfato de 8-flúor-2{4-[(metilamino)metil]fenil}-1,3,4,5-tetraidro- 6h-azepino[5,4,3-cd]indol-6-ona, composição farmacêutica, formas de dosagens e respectivo uso |
JP2008513435A (ja) * | 2004-09-22 | 2008-05-01 | ファイザー・インク | ポリ(adp−リボース)ポリメラーゼ阻害剤を含む治療用組成物 |
MX2007008771A (es) | 2005-01-19 | 2007-09-11 | Mgi Gp Inc | Compuestos de diazabenzo [des] antracen-3-ona y metodos para inhibir parp. |
ZA200800907B (en) | 2005-07-18 | 2010-04-28 | Bipar Sciences Inc | Treatment of cancer |
US20100279327A1 (en) * | 2006-06-12 | 2010-11-04 | Bipar Sciences, Inc. | Method of treating diseases with parp inhibitors |
US8143447B2 (en) | 2006-09-05 | 2012-03-27 | Bipar Sciences, Inc. | Treatment of cancer |
WO2008030891A2 (en) | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Inhibition of fatty acid synthesis by parp inhibitors and methods of treatment thereof |
JP5439380B2 (ja) | 2007-10-03 | 2014-03-12 | エーザイ インク. | Parp阻害化合物、組成物及び使用方法 |
MX2010005221A (es) * | 2007-11-12 | 2010-09-28 | Bipar Sciences Inc | Tratamiento de cancer de utero y cancer de ovario con un inhibidor de parp solo o en combinacion con agentes antitumorales. |
EP2217227B1 (en) | 2007-11-12 | 2013-08-21 | BiPar Sciences, Inc. | Treatment of breast cancer with 4-iodo-3-nitrobenzamide in combination with anti-tumor agents |
RU2010136966A (ru) * | 2008-02-04 | 2012-03-20 | Байпар Сайенсиз, Инк. (Us) | Способы диагностики и лечения заболеваний, опосредованных parp |
GB0804755D0 (en) | 2008-03-14 | 2008-04-16 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
WO2011058367A2 (en) | 2009-11-13 | 2011-05-19 | Astrazeneca Ab | Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor |
EP4166558A1 (en) | 2010-02-12 | 2023-04-19 | Pfizer Inc. | Salts and polymorphs of 8-fluoro-2-{4- [(methylamino)methyl]phenyl}-1 ,3,4,5-tetrahydro-6h-azepino[5,4,3- cd]indol-6-one |
DK3012329T3 (da) | 2010-06-18 | 2017-11-20 | Myriad Genetics Inc | Fremgangsmåder og materialer til at vurdere tab af heterozygositet |
US9512485B2 (en) | 2010-08-24 | 2016-12-06 | Dana-Farber Cancer Institute. Inc. | Methods for predicting anti-cancer response |
EP2646428B1 (en) | 2010-12-02 | 2016-06-01 | Shanghai De Novo Pharmatech Co Ltd. | Heterocyclic derivatives, preparation processes and medical uses thereof |
EP2709618A4 (en) * | 2011-05-10 | 2014-11-05 | UNIVERSITé LAVAL | METHOD FOR THE TREATMENT AND DIAGNOSIS OF PULMONARY ARTERIAL HYPERTENSION |
CA2839210A1 (en) | 2011-06-17 | 2012-12-20 | Myriad Genetics, Inc. | Methods and materials for assessing allelic imbalance |
MX368261B (es) | 2011-07-22 | 2019-09-25 | Pacylex Pharmaceuticals Inc | Letalidad sintetica y el tratamiento de cancer. |
FI2794907T4 (fi) | 2011-12-21 | 2023-03-27 | Menetelmiä ja materiaaleja heterotsygoottisuuden menettämisen arvioimiseksi | |
DK2817630T3 (en) | 2012-02-23 | 2018-10-08 | Childrens Medical Center | Methods for predicting an anti-cancer response |
ES2658867T3 (es) | 2012-06-07 | 2018-03-12 | Institut Curie | Métodos para detectar la inactivación de la ruta de recombinación homóloga (BRCA1/2) en tumores humanos |
CN104754942A (zh) * | 2012-09-05 | 2015-07-01 | 拜尔农作物科学股份公司 | 取代的苯并二氮杂卓酮和苯并氮杂卓酮或它们的盐作为对抗植物非生物胁迫的活性物质的用途 |
US10308986B2 (en) | 2013-03-14 | 2019-06-04 | Children's Medical Center Corporation | Cancer diagnosis, treatment selection and treatment |
JP6625045B2 (ja) | 2013-04-05 | 2019-12-25 | ミリアド・ジェネティックス・インコーポレイテッド | 相同組換え欠損を評価するための方法および材料 |
EP3080292B1 (en) | 2013-12-09 | 2022-02-02 | Institut Curie | Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors |
EP3686288B1 (en) | 2014-08-15 | 2023-03-08 | Myriad Genetics, Inc. | Methods and materials for assessing homologous recombination deficiency |
CN106794185A (zh) | 2014-08-22 | 2017-05-31 | 克洛维斯肿瘤有限公司 | Rucaparib的高剂量强度片剂 |
KR20160116831A (ko) | 2015-03-31 | 2016-10-10 | (주)아모레퍼시픽 | 코지산 유도체를 유효성분으로 포함하는 장수 유전자 활성화용 조성물 |
PL3325662T3 (pl) | 2015-07-17 | 2024-02-26 | Pacylex Pharmaceuticals Inc. | Wyciszenie epigenetyczne nmt2 |
PT3325623T (pt) | 2015-07-23 | 2019-09-04 | Inst Curie | Utilização de uma combinação de molécula dbait e de inibidores de parp para o tratamento do cancro |
GB201519573D0 (en) | 2015-11-05 | 2015-12-23 | King S College London | Combination |
TWI730013B (zh) | 2015-11-20 | 2021-06-11 | 生華生物科技股份有限公司 | 用於治療癌症的四環喹諾酮類似物組合療法 |
WO2017156350A1 (en) | 2016-03-09 | 2017-09-14 | K-Gen, Inc. | Methods of cancer treatment |
EP3786171A1 (en) | 2016-04-01 | 2021-03-03 | Nohms Technologies, Inc. | Modified ionic liquids containing phosphorus |
WO2018022851A1 (en) | 2016-07-28 | 2018-02-01 | Mitobridge, Inc. | Methods of treating acute kidney injury |
AU2017355402A1 (en) | 2016-11-02 | 2019-05-30 | Health Research, Inc. | Combination treatment with antibody-drug conjugates and PARP inhibitors |
WO2018162439A1 (en) | 2017-03-08 | 2018-09-13 | Onxeo | New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule |
WO2018165615A1 (en) | 2017-03-09 | 2018-09-13 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Parp-1 and methods of use thereof |
US20200129476A1 (en) | 2017-04-28 | 2020-04-30 | Akribes Biomedical Gmbh | PARP Inhibitor in Combination with a Glucocorticoid and/or Ascorbic Acid and/or a Protein Growth Factor for the Treatment of Impaired Wound Healing |
US10665899B2 (en) | 2017-07-17 | 2020-05-26 | NOHMs Technologies, Inc. | Phosphorus containing electrolytes |
MA51524A (fr) | 2018-01-05 | 2020-11-11 | Cybrexa 1 Inc | Composés, compositions et méthodes pour le traitement de maladies impliquant des tissus malades acides ou hypoxiques |
US20190374550A1 (en) | 2018-02-15 | 2019-12-12 | Senhwa Biosciences, Inc. | Quinolone analogs and their salts, compositions, and method for their use |
JP2021515580A (ja) | 2018-03-13 | 2021-06-24 | オンクセオOnxeo | がんの治療における獲得耐性に対抗するdbait分子 |
WO2019195658A1 (en) | 2018-04-05 | 2019-10-10 | Dana-Farber Cancer Institute, Inc. | Sting levels as a biomarker for cancer immunotherapy |
CN114341162A (zh) | 2019-07-10 | 2022-04-12 | 赛博克萨2公司 | 作为治疗剂的细胞毒素的肽缀合物 |
PE20220485A1 (es) | 2019-07-10 | 2022-04-04 | Cybrexa 3 Inc | Conjugados peptidicos de agentes dirigidos a microtubulos como terapeuticos |
WO2021018298A1 (zh) * | 2019-08-01 | 2021-02-04 | 南京明德新药研发有限公司 | 作为parp抑制剂吲哚并七元酰肟化合物 |
WO2021041532A1 (en) | 2019-08-26 | 2021-03-04 | Dana-Farber Cancer Institute, Inc. | Use of heparin to promote type 1 interferon signaling |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
CN115485271A (zh) | 2020-04-28 | 2022-12-16 | 理森制药股份公司 | 用作聚(adp-核糖)聚合酶(parp)抑制剂的新型化合物 |
WO2022090938A1 (en) | 2020-10-31 | 2022-05-05 | Rhizen Pharmaceuticals Ag | Phthalazinone derivatives useful as parp inhibitors |
AU2022255809A1 (en) | 2021-04-08 | 2023-10-26 | Incozen Therapeutics Pvt. Ltd. | Inhibitors of poly(adp-ribose) polymerase |
EP4141127A1 (en) | 2021-08-30 | 2023-03-01 | Zentrum Familiärer Brust- und Eierstockkrebs Universitätsklinik Köln | Method for assessing homologous recombination deficiency in ovarian cancer cells |
WO2023201338A1 (en) | 2022-04-15 | 2023-10-19 | Ideaya Biosciences, Inc. | Combination therapy comprising a mat2a inhibitor and a parp inhibitor |
WO2023233295A1 (en) | 2022-06-01 | 2023-12-07 | Ideaya Biosciences, Inc. | Thiadiazolyl derivatives as dna polymerase theta inhibitors and uses thereof |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ512731A (en) * | 1999-01-11 | 2004-01-30 | Agouron Pharma | Tricyclic inhibitors of poly(ADP-ribose) polymerases |
ECSP003637A (es) * | 1999-08-31 | 2002-03-25 | Agouron Pharma | Inhibidores triciclicos de poli (adp-ribosa) polimerasas |
US7449464B2 (en) * | 2003-03-12 | 2008-11-11 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
BRPI0408996A (pt) * | 2003-03-31 | 2006-03-28 | Pfizer | saia de inibidores tricìclicos de poli(adpp-ribose) polimerases |
MXPA06000993A (es) | 2003-07-25 | 2006-08-31 | Cancer Rec Tech Ltd | Inhbidores triciclicos de parp. |
GB0317466D0 (en) | 2003-07-25 | 2003-08-27 | Univ Sheffield | Use |
DK2305221T3 (en) * | 2003-12-01 | 2015-08-24 | Kudos Pharm Ltd | DNA damage repair inhibitors for the treatment of cancer |
JP2008513435A (ja) * | 2004-09-22 | 2008-05-01 | ファイザー・インク | ポリ(adp−リボース)ポリメラーゼ阻害剤を含む治療用組成物 |
-
2004
- 2004-07-23 MX MXPA06000993A patent/MXPA06000993A/es active IP Right Grant
- 2004-07-23 ES ES04743516T patent/ES2339663T3/es active Active
- 2004-07-23 DK DK04743516.9T patent/DK1660095T3/da active
- 2004-07-23 SI SI200431370T patent/SI1660095T1/sl unknown
- 2004-07-23 CA CA2533332A patent/CA2533332C/en active Active
- 2004-07-23 KR KR1020067001725A patent/KR101138471B1/ko active IP Right Grant
- 2004-07-23 RU RU2006105652/04A patent/RU2404183C2/ru active
- 2004-07-23 PL PL04743516T patent/PL1660095T3/pl unknown
- 2004-07-23 JP JP2006521648A patent/JP5466814B2/ja active Active
- 2004-07-23 US US10/898,653 patent/US7351701B2/en active Active
- 2004-07-23 NZ NZ544989A patent/NZ544989A/en unknown
- 2004-07-23 EP EP04743516A patent/EP1660095B1/en active Active
- 2004-07-23 PT PT04743516T patent/PT1660095E/pt unknown
- 2004-07-23 BR BRPI0412899-0A patent/BRPI0412899B1/pt not_active IP Right Cessation
- 2004-07-23 WO PCT/GB2004/003183 patent/WO2005012305A2/en active Application Filing
- 2004-07-23 AU AU2004261462A patent/AU2004261462B2/en active Active
- 2004-07-23 US US10/565,308 patent/US7531530B2/en active Active
- 2004-07-23 AT AT04743516T patent/ATE454893T1/de active
- 2004-07-23 DE DE602004025123T patent/DE602004025123D1/de active Active
-
2006
- 2006-01-24 ZA ZA2006/00679A patent/ZA200600679B/en unknown
- 2006-01-24 IL IL173336A patent/IL173336A/en active IP Right Grant
- 2006-02-24 NO NO20060928A patent/NO334610B1/no unknown
- 2006-06-19 HK HK06106961.6A patent/HK1084602A1/xx unknown
-
2010
- 2010-03-31 CY CY20101100309T patent/CY1110335T1/el unknown
-
2011
- 2011-11-29 JP JP2011260401A patent/JP5580280B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1084602A1 (en) | Tricyclic parp inhibitors | |
WO2002044183A3 (en) | Benzoazepine and benzodiazepine derivatives and their use as parp inhibitors | |
TW200407322A (en) | Novel imidazopyridines as cyclin dependent kinase inhibitors | |
HUP0500574A3 (en) | Acridone inhibitors of impdh enzyme, pharmaceutical compositions containing them and their use | |
TW200740803A (en) | Heterocyclic derivatives as modulators of ion channels | |
IL181700A0 (en) | Quinazoline derivatives and pharmaceutical compositions containing the same | |
ZA200710332B (en) | Bicyclic derivatives as modulators of ion channels | |
SG145695A1 (en) | Pyridyl derivatives and their use as therapeutic agents | |
SG145700A1 (en) | Pyridyl derivatives and their use as therapeutic agents | |
HK1093064A1 (en) | Thienopyrimidine derivatives as potassium channel inhibitors | |
ZA200706029B (en) | Tricyclic &-opioid domulators | |
MXPA03008045A (es) | Nuevas composiciones de medicamentos en base a agentes anticolinergicos e inhibidores de pde-iv. | |
HUP0501182A3 (en) | Aza spiro alkane derivatives as inhibitors of metallproteases and pharmaceutical compositions containing them | |
HUP0203288A3 (en) | Pyrrole derivatives as phosphodiesterase vii inhibitors, pharmaceutical compositions containing them and their use | |
IL179206A0 (en) | Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same | |
AU2003226724A8 (en) | Quinoline and aza-indole derivatives and their use as 5-ht6 ligands | |
HUP0203245A3 (en) | Imidazopyridine derivatives as phosphodiesterase vii inhibitors and pharmaceutical compositions containing them | |
EP1244452A4 (en) | UROTENSIN II RECEPTOR ANTAGONISTS | |
MY136840A (en) | Pyrazolopyridines as cyclin dependent kinase inhibitors | |
MXPA05012953A (es) | Benzo[b]tiofenos 3-arilsulfanil y 3-heteroarilsulfanil sustituidos como agentes terapeuticos. | |
ZA201000581B (en) | 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6-carboxamide and 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]-diazepine-7-carboxamide derivatives,preparation and therapeutic use thereof | |
WO2002011732A8 (en) | Novel bicyclic and tricyclic pyrrolidine derivatives as gnrh antagonists | |
HUP0301173A3 (en) | Quinazoline derivatives and their use for the preparation of pharmaceutical compositions inhibiting parp enzyme | |
HUP0400546A3 (en) | Tricyclic derivatives of indole with antiangiogenic activity and pharmaceutical compositions containing them | |
MXPA03011167A (es) | Derivados de carbolina utiles como ihibidores de pdev. |